In deriving these US Biotechnology Corps, I first started with the very helpful Yahoo Finance Website Biotechnology Sector .
The historical stock prices of these companies were obtained from the following two excellent internet resources.... Google Finance and MarketWatch Big Charts.
These 40 largest US Biotechnology Companies had their average stock prices drop by a huge 37% from December 31, 2007 during President Bush's second Presidential term, and very early in President Obama's first term, or on March 6, 2009, which was these US Biotechnology Corps' very lowest point due to the spillover effects resulting from the disastrous 2008 Financial Meltdown.
But nearly miraculously since March 6, 2009, the average stock prices of these same 40 largest US Biotechnology Corps have increased by an off-the-charts 1,212% through January 17, 2014.
Clearly, the investors in and employees of these 40 US largest US Biotechnology Companies must be extremely pleased with the impact of actions taken by both the Obama Administration and the US Fed to successfully rescue the US economy from its extremely weakened state.
Of these 40 US Biotech companies, 17 of them are headquartered in California and 11 of them in Massachusetts.
In the first chart below are the market prices of each of these 40 largest US Biotechnology Companies on January 17, 2014, on March 6, 2009, and on December 31, 2007, sorted by Percentage Increase from March 6, 2009 to January 17, 2014:
| Market | Market | ||||||
| Price | Price | ||||||
| % | % | ||||||
| Change | Change | ||||||
| Market | Market | Market | 3-6-09 | 12-31-07 | |||
| Price | Price | Price | to | to | |||
| Biotechnology Company | HQs | 1-17-14 | 3-6-09 | 12-31-07 | 1-17-14 | 3-6-09 | |
| Jazz Pharmaceuticals | Palo Alto | CA | 150.02 | 0.62 | 14.70 | 24097% | -96% |
| ACADIA Pharmaceuticals | San Diego | CA | 24.04 | 0.80 | 11.07 | 2905% | -93% |
| Incyte | Wilmington | DE | 61.87 | 2.14 | 10.05 | 2791% | -79% |
| Regeneron Pharmaceuticals | Tarreytown | NY | 292.00 | 12.67 | 24.15 | 2205% | -48% |
| Exact Sciences | Madison | WI | 14.31 | 0.77 | 3.22 | 1756% | -76% |
| Synageva BioPharma | Lexington | MA | 96.48 | 6.70 | 34.90 | 1340% | -81% |
| ViroPharma | Exton | PA | 49.99 | 4.08 | 7.94 | 1125% | -49% |
| Questcor Pharmaceuticals | Anaheim | CA | 59.32 | 5.02 | 5.77 | 1082% | -13% |
| Novavax | Rockville | MD | 6.13 | 0.56 | 3.33 | 995% | -83% |
| Medivation | San Francisco | CA | 75.11 | 7.64 | 7.20 | 883% | 6% |
| NPS Pharmaceuticals | Bedminster | NJ | 35.67 | 4.06 | 3.83 | 779% | 6% |
| Alexion Phramaceuticals | Cheshire | CT | 139.71 | 16.14 | 18.76 | 766% | -14% |
| BioMarin Pharmaceutical | San Rafael | CA | 73.45 | 10.22 | 35.40 | 619% | -71% |
| Sarepta Therapeutics | Cambridge | MA | 26.78 | 3.78 | 8.46 | 608% | -55% |
| Biogen Idec | Cambridge | MA | 297.48 | 44.23 | 56.92 | 573% | -22% |
| Seattle Genetics | Bothell | WA | 47.95 | 7.23 | 11.40 | 563% | -37% |
| Sangamo Biosciences | Richmond | CA | 19.65 | 2.99 | 13.02 | 557% | -77% |
| Ariad Pharmaceuticals | Cambridge | MA | 6.90 | 1.20 | 4.25 | 475% | -72% |
| Alnylam Pharmaceuticals | Cambridge | MA | 87.36 | 15.79 | 29.08 | 453% | -46% |
| Celldex Therapeutics | Needham | MA | 28.32 | 5.35 | 6.00 | 429% | -11% |
| Dyax | Burlington | MA | 9.42 | 2.17 | 3.66 | 334% | -41% |
| Illumina | San Diego | CA | 136.34 | 31.98 | 29.63 | 326% | 8% |
| Celgene | Summit | NJ | 167.04 | 41.16 | 46.21 | 306% | -11% |
| Halozyme Therapeutics | San Diego | CA | 17.03 | 4.66 | 7.11 | 265% | -34% |
| Gilead Sciences | Foster City | CA | 78.40 | 22.01 | 23.01 | 256% | -4% |
| ImmunoGen | Waltham | MA | 16.14 | 4.91 | 4.15 | 229% | 18% |
| Theravance | South San Fran | CA | 38.14 | 12.15 | 19.50 | 214% | -38% |
| Nektar Therapeutics | San Francisco | CA | 13.06 | 4.21 | 6.71 | 210% | -37% |
| Idenix Pharmaceuticals | Cambridge | MA | 8.01 | 2.67 | 2.70 | 200% | -1% |
| Vertex Pharmaceuticals | Cambridge | MA | 82.09 | 27.77 | 23.23 | 196% | 20% |
| MannKind | Valencia | CA | 5.79 | 2.17 | 7.96 | 167% | -73% |
| Amgen | Thousand Oaks | CA | 119.15 | 46.38 | 46.44 | 157% | 0% |
| Charles River Laboratories | Wilmington | MA | 58.70 | 25.12 | 65.80 | 134% | -62% |
| Techne | Minneapolis | MN | 95.38 | 46.98 | 66.05 | 103% | -29% |
| Cadence Pharmaceuticals | San Diego | CA | 11.73 | 5.83 | 14.86 | 101% | -61% |
| Exelixis | South San Fran | CA | 8.08 | 4.34 | 8.63 | 86% | -50% |
| Arena Pharmaceuticals | San Diego | CA | 7.26 | 4.06 | 7.83 | 79% | -48% |
| PDL BioPharma | Incline Village | NV | 8.97 | 6.27 | 12.46 | 43% | -50% |
| Intermune | Brisbane | CA | 17.92 | 13.63 | 13.33 | 31% | 2% |
| Acorda Therapeutics | Ardsley | NY | 30.50 | 23.44 | 21.96 | 30% | 7% |
| Average % Change all 40 | 1212% | -37% |
Jazz Pharmaceuticals is legally headquartered in the Ireland tax haven, but with substantial operations in the US. When I exclude the outsized stock appreciation of Jazz Pharmaceuticals, the average stock price increase for the remaining 39 US Biotechnology companies was a still very impressive 625% from March 6, 2009 to the most recent date January 17, 2014.
But it's not just the above 40 Biotechs which are doing just great.
There are another 12 US Biotechs which had IPOs since March 6, 2009 and which now have Market Capitalizations of at least $1 bil each. Four of these 12 are located in the medical research hotbed of Cambridge, MA.
The below chart shows the market prices on the most recent date January 17, 2014 and also on the close of the first trading date of the 12 additional US Biotech companies with current Total Market Capitalizations of at least $1 bil each and which didn't have their common stocks trading on March 6, 2009:
| Month | Price | |||||||
| Of | On | |||||||
| Market | First | First | ||||||
| Price | Trading | Trading | % | |||||
| Biotechnology Company | HQs | 1-17-14 | Date | Date | Change | |||
| Puma Biotechnology | Los Angeles | CA | 125.81 | Jun 2012 | 12.50 | 906% | ||
| Clovis Oncology | Boulder | CO | 72.90 | Nov 2011 | 12.56 | 480% | ||
| Aegerion Pharmaceuticals | Cambridge | MA | 62.51 | Oct 2010 | 10.80 | 479% | ||
| INSYS Therapeutics | Phoenix | AZ | 53.81 | May 2013 | 9.50 | 466% | ||
| Acceleron Pharma | Cambridge | MA | 49.14 | Sep 2013 | 19.99 | 146% | ||
| Tesaro | Waltham | MA | 32.82 | Jun 2012 | 13.69 | 140% | ||
| Portola Pharmaceuticals | South San Fran | CA | 27.72 | May 2013 | 15.15 | 83% | ||
| Epizyme | Cambridge | MA | 37.59 | May 2013 | 22.99 | 64% | ||
| MacroGenics | Rockville | MD | 40.21 | Oct 2013 | 24.99 | 61% | ||
| Intrexon | Germantown | MD | 36.82 | Aug 2013 | 24.73 | 49% | ||
| OncoMed Pharmaceuticals | Redwood City | CA | 37.00 | July 2013 | 27.18 | 36% | ||
| Agios Pharmaceuticals | Cambridge | MA | 35.93 | Jul 2013 | 31.28 | 15% |
These recent IPOs with a current Market Capitalization of at least $1 bil each has grown like weeds.....in fact, one of them INSYS Therapeutics literally. Of the above 12 IPOs, one of them went public in both 2010 and 2011, two of them in 2012, and a substantially higher eight of them in 2013.
Clearly, US Biotech companies have done extremely well during the Obama Administration, and it appears that they have really picked up steam in the most recent year. This is a very good development, not just for better US health, but also for the US economy.
